NO20015396L - Use of soluble costimulatory molecules to enhance immune responses - Google Patents

Use of soluble costimulatory molecules to enhance immune responses

Info

Publication number
NO20015396L
NO20015396L NO20015396A NO20015396A NO20015396L NO 20015396 L NO20015396 L NO 20015396L NO 20015396 A NO20015396 A NO 20015396A NO 20015396 A NO20015396 A NO 20015396A NO 20015396 L NO20015396 L NO 20015396L
Authority
NO
Norway
Prior art keywords
immune responses
costimulatory molecules
enhance immune
soluble costimulatory
soluble
Prior art date
Application number
NO20015396A
Other languages
Norwegian (no)
Other versions
NO20015396D0 (en
Inventor
Knut Sturmhoefel
Stanley F Wolf
Margot O'toole
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of NO20015396D0 publication Critical patent/NO20015396D0/en
Publication of NO20015396L publication Critical patent/NO20015396L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20015396A 1999-05-06 2001-11-05 Use of soluble costimulatory molecules to enhance immune responses NO20015396L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13294499P 1999-05-06 1999-05-06
PCT/US2000/012435 WO2000067788A2 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses

Publications (2)

Publication Number Publication Date
NO20015396D0 NO20015396D0 (en) 2001-11-05
NO20015396L true NO20015396L (en) 2002-01-02

Family

ID=22456295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015396A NO20015396L (en) 1999-05-06 2001-11-05 Use of soluble costimulatory molecules to enhance immune responses

Country Status (15)

Country Link
EP (1) EP1181053A2 (en)
JP (1) JP2002544170A (en)
KR (1) KR20020001865A (en)
CN (1) CN1377279A (en)
AU (1) AU4825700A (en)
BR (1) BR0010711A (en)
CA (1) CA2373256A1 (en)
CZ (1) CZ20013964A3 (en)
HK (1) HK1041810A1 (en)
HU (1) HUP0201222A3 (en)
IL (1) IL146106A0 (en)
NO (1) NO20015396L (en)
PL (1) PL360915A1 (en)
WO (1) WO2000067788A2 (en)
ZA (1) ZA200109376B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
JP3871503B2 (en) 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
JP4210454B2 (en) 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
JP3597140B2 (en) 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
JP4212278B2 (en) 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
CN101213199B (en) * 2005-06-30 2013-12-18 卫材R&D管理有限公司 Compounds for preparing immunological adjuvant
JP2009518427A (en) 2005-12-08 2009-05-07 ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド In vivo cell surface manipulation
EP1973573B1 (en) 2005-12-08 2013-05-22 University of Louisville Research Foundation, Inc. Methods and compositions for expanding t regulatory cells
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US20130039954A1 (en) * 2011-07-29 2013-02-14 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
JP2015513915A (en) * 2012-04-02 2015-05-18 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Recombinant bacteria for the induction of cellular immune responses
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
TR201908418T4 (en) 2013-11-04 2019-07-22 Uti Lp Methods and compositions for sustainable immunotherapy.
KR20180011135A (en) 2015-05-06 2018-01-31 유티아이 리미티드 파트너쉽 Nanoparticle composition for continuous therapy
CN110743006B (en) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 Composition for synergistically relieving immune cell failure and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521053A (en) * 1998-07-28 2002-07-16 マイクロメット アーゲー Heteromini body

Also Published As

Publication number Publication date
WO2000067788A2 (en) 2000-11-16
CN1377279A (en) 2002-10-30
HUP0201222A2 (en) 2002-08-28
NO20015396D0 (en) 2001-11-05
EP1181053A2 (en) 2002-02-27
PL360915A1 (en) 2004-09-20
IL146106A0 (en) 2002-07-25
CZ20013964A3 (en) 2002-06-12
CA2373256A1 (en) 2000-11-16
WO2000067788A3 (en) 2001-04-05
HUP0201222A3 (en) 2004-07-28
BR0010711A (en) 2002-02-13
KR20020001865A (en) 2002-01-09
AU4825700A (en) 2000-11-21
HK1041810A1 (en) 2002-07-26
ZA200109376B (en) 2003-03-13
JP2002544170A (en) 2002-12-24

Similar Documents

Publication Publication Date Title
NO20015396D0 (en) Use of soluble costimulatory molecules to enhance immune responses
NO20004133D0 (en) Antibodies to human CD40
NO20020799L (en) Device for extracting a substance for the preparation of a drink
NO20012312L (en) Infrared imaging to detect components of hygiene items
DE60036968D1 (en) Adamantane derivatives for the treatment of inflammatory, immunological and cardiovascular diseases
NO20030443L (en) Process for Preparation of Functional Protein Domains
HUP0301477A3 (en) Antibodies to human mcp-1 molecule
NO20020779D0 (en) Methods, preparations and kits to promote healing of central nervous system damage
AU6949800A (en) Compositions and methods for the treatment of sepsis using antibodies to c5a
IS6575A (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives to treat pain
NO20015542L (en) Process for the preparation and use of N-desmethylzopiclones
NO20022319D0 (en) Use of fatty acids by alkoxylated oligoamines to improve the lubricity of petroleum products
NO20021159D0 (en) Method of interferometric processing to identify layer boundaries
AU2086501A (en) Inducing cellular immune responses to carcinoembryonic antigen using peptide andnucleic acid compositions
IS6381A (en) Novelty in the use of antibodies in vaccines
IS6574A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives to treat pain
NO20010842L (en) Connecting element for connecting two components
NO20003138D0 (en) New application of local anesthetics to vascular headaches
AU2001261133A1 (en) Detection of antibodies to gangliosides
AU2002249917A1 (en) Induction of immune responses to isoaspartyl-modified antigens
AU6019599A (en) Use of mcrp to enhance immune responses
NO20011412D0 (en) Methods for down-modulating the immune response to therapeutic proteins
NO20032297D0 (en) Process for the preparation of distamycin derivatives
IT247660Y1 (en) DEVICE TO SUPPORT ARMS OF CONSTIPATION BENCHES.
NO20020560L (en) Process for the preparation of cyclohexanecarboxylic acids

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application